SEC Form 4 · accession 0001193125-26-330668
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Atabak Mokari
Officer — Chief Financial Officer
Period of report
Jul 30, 2026
Accepted (ET)
Aug 3, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 30, 2026 | M | 80,000 | $23.06 | A | 96,130 | D | |
| Common StockF3,F1 | Jul 30, 2026 | S | 4,200 | $105.5352 | D | 91,930 | D | |
| Common StockF4,F1 | Jul 30, 2026 | S | 8,956 | $106.9553 | D | 82,974 | D | |
| Common StockF1 | Jul 30, 2026 | S | 400 | $108.46 | D | 82,574 | D | |
| Common StockF5,F1 | Jul 30, 2026 | S | 2,202 | $110.0283 | D | 80,372 | D | |
| Common StockF1 | Jul 30, 2026 | S | 600 | $110.95 | D | 79,772 | D | |
| Common StockF6,F1 | Jul 30, 2026 | S | 4,700 | $113.1789 | D | 75,072 | D | |
| Common StockF7,F1 | Jul 30, 2026 | S | 15,477 | $114.9601 | D | 59,595 | D | |
| Common StockF8,F1 | Jul 30, 2026 | S | 14,222 | $115.8669 | D | 45,373 | D | |
| Common StockF9,F1 | Jul 30, 2026 | S | 7,089 | $116.9561 | D | 38,284 | D | |
| Common StockF10,F1 | Jul 30, 2026 | S | 8,267 | $117.9329 | D | 30,017 | D | |
| Common StockF11,F1 | Jul 30, 2026 | S | 4,783 | $118.7346 | D | 25,234 | D | |
| Common StockF12,F1 | Jul 30, 2026 | S | 8,103 | $119.9481 | D | 17,131 | D | |
| Common StockF13,F1 | Jul 30, 2026 | S | 1,001 | $120.6749 | D | 16,130 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F14 | $23.06 | Jul 30, 2026 | M | 80,000 | D | — | Feb 13, 2033 | Common Stock | 80,000 | 95,833 | D |
Explanation of responses
- F1Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F10Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.41 to $118.39 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F11Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.42 to $119.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F12Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.42 to $120.41 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F13Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $120.49 to $120.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F14Fully exercisable.
- F2This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
- F3Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $105.305 to $106.2 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $106.75 to $107.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F5Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.71 to $110.42 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F6Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.96 to $113.89 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F7Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.305 to $115.30 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F8Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.35 to $116.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F9Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.35 to $117.3 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Remarks
The power of attorney under which this form was signed is on file with the Commission.